US STOCKS-Wall St set to open higher on hopes of stimulus, rebound

* Investors await nonfarm payroll, manufacturing activity
data
* Boeing gains as MAX 737 test flights slated to start
* Futures up: Dow 0.81%, S&P 0.51%, Nasdaq 0.07%

(Adds comment, details; updates prices)
By Pawel Goraj and Devik Jain
June 29 (Reuters) - Wall Street's main indexes were set to
rise on Monday following a selloff last week as investors
weighed hopes of more stimulus and improving data against a
resurgence in global coronavirus cases.
The three indexes had tumbled more than 2% on Friday as
several U.S. states imposed business restrictions in response to
the surge in COVID-19 cases. The global death toll from the
respiratory illness crossed half a million on Sunday, with about
one-quarter of them in the United States. MKTS/GLOB
The benchmark S&P 500 .SPX has rallied since a
coronavirus-driven crash in March, up about 16% since April and
set for its best quarter since 1998, partly on a raft of U.S.
fiscal and monetary stimulus.
This week, investors will focus on employment, consumer
confidence and manufacturing data for June for signs of whether
the U.S. economy will continue to rebound after indications of a
pickup in May.
"The market is taking a tremendous amount of comfort in the
fact that as long as we contain the virus, the economy is going
to recover very fast and you're going to see cyclical stocks
start to rally again," said Thomas Hayes, managing member at
Great Hill Capital LLC in New York.
At 8:06 a.m. ET, Dow e-minis 1YMcv1 were up 203 points, or
0.81%, S&P 500 e-minis EScv1 were up 15.25 points, or 0.51%
and Nasdaq 100 e-minis NQcv1 were up 6.75 points, or 0.07%.
Among stocks, Boeing Co BA.N rose 7.5% in premarket trade
after the Federal Aviation Administration confirmed on Sunday it
had approved key certification test flights for the grounded 737
MAX that could begin as soon as Monday. Boeing suppliers were also up, with Spirit AeroSystems
Holdings Inc SPR.N rising 5.7%.
Gilead Sciences Inc GILD.O edged 2.8% higher as it priced
its COVID-19 drug candidate remdesivir at $2,340 for a five-day
treatment in the United States and some other developed
countries. Facebook Inc FB.O looked set to extend declines from
Friday as a report said PepsiCo Inc PEP.O was set to join a
growing number of companies pulling ad dollars from the social
media platform.